Navigation Links
USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
Date:12/11/2008

VIENNA, Austria, Dec. 11 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced the execution of a contract modification with the U.S. Department of Health and Human Services (HHS). The agreement commits additional funding of USD 12.5 m for Intercell's Pandemic Influenza program.

Intercell is developing a Pandemic Influenza Vaccine Patch System that includes an immunostimulant patch administered in conjunction with an injected Pandemic Influenza vaccine (manufactured by Solvay Biologicals, B.V., The Netherlands); the system is designed to enhance the immune response and enable dose sparing of the Pandemic Influenza vaccine.

The actual funding forms part of an HHS contract with potential funding of up to USD 128 m over five years. If successful, Intercell's Pandemic Influenza Vaccine Patch System would have the effect of expanding limited vaccine supplies by allowing fewer or lower doses of the vaccine.

The next Phase II study is expected to start in early 2009 and will be a randomized, blinded study to determine the optimal combination and dose of an injected H5N1 influenza vaccine and the vaccine patch from Intercell. The study will be conducted in the U.S. and is expected to enroll 500 subjects at six study sites.

The initial Phase I/II clinical trial funded under this HHS contract demonstrated that a single 45-microgram dose of an injected H5N1 influenza vaccine, coupled with a single 50-microgram Intercell patch was sufficient to provide an immune response considered protective in 73 percent of those tested: a statistically significant improvement over those who received the H5N1 influenza vaccine alone. The trial was one of the first to demonstrate that a single dose of Pandemic Influenza vaccine may meet the level of protection suggested in U.S. Food and Drug Administration (FDA) guidance.

Thomas Lingelbach, COO of Intercell AG and CEO of Intercell USA commented: "T
'/>"/>

SOURCE Intercell AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
2. Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
3. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
4. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
5. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
6. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
7. Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
8. California Stem Cell Agency Exaggerated Its Role in Funding Key Research
9. Continued Funding to Help Advance Exciting Moment in Diabetes Research
10. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
11. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Alvarado Hospital unveiled its new facility ... & Joint Institute. The institute is entirely devoted ... surgery and joint replacement. The Spine & Joint ... experience-focused approach. For example, patients are encouraged to ... than patient gowns. "From the ...
(Date:7/29/2015)... LAKE FOREST, Calif. , July 29, ... ) ("Cryoport" or the "Company"), the leading ... the life sciences industry, serving markets including ... organizations, vaccine manufacturers, animal health, and reproductive ... completed the sale of common stock and warrants ...
(Date:7/29/2015)...  Ortho-Clinical Diagnostics, Inc. (OCD) today announced the presentation ... address a range of important tests for clinical labs ... The scientific posters will be delivered during the 2015 ... held July 26 - 30 in Atlanta, ... is emerging stronger than ever since becoming a stand-alone ...
Breaking Medicine Technology:The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3
... DIEGO, Feb. 11, 2011 Conatus Pharmaceuticals Inc. today ... Preferred Stock private placement financing.  This financing was led ... and included participation by existing investors; Aberdare Ventures, Advent ... Roche Venture Fund.  Conatus will use the proceeds to ...
... LOS ANGELES, Feb. 11, 2011 Nationally-acclaimed researcher and ... speech at the 11th National Conference on Cancer Nursing ... potentially deadly infections they were supposed to prevent. ... needleless IV connector devices with silver coated or silver ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research 2
(Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
(Date:7/30/2015)... ... July 30, 2015 , ... After a three year trial designed to ... commonly known as the “bionic eye,” researchers have determined the trial to be a ... patients facing or already affected by complete vision loss as a result of Retinitis ...
(Date:7/30/2015)... ... July 30, 2015 , ... According to Chicago ... find a complete removable denture acceptable. The demand for dental implants is rising ... less expensive, immediate loading techniques will have the ability to offer the patient ...
(Date:7/30/2015)... ... 2015 , ... When trying to gain weight, many people place a lot of focus on the different types ... to be consumed. However, another key component to successful weight gain is knowing when ... this, CB-1 Weight Gainer gives three tips on when to eat to gain weight. ...
(Date:7/30/2015)... ... ... PeopleKeys, a company with over 30 years of experience in behavioral analysis, ... the newest installment in their popular DISC for the Real World series, will air ... webinar is intended for people interested in training others to use DISC behavioral analysis ...
Breaking Medicine News(10 mins):Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3Health News:PeopleKeys to Air “Managing Stress: Train the Trainer” DISC Webinar 2
... WASHINGTON, April 8, 2008 The following is a,statement ... Governor Ted Strickland and Ohio legislators have abandoned ... their underhanded actions today to,raid funds from the Ohio ... to come more Ohio children will become addicted to,tobacco, ...
... Important to Protect Animal, Human Health, WASHINGTON, ... today launched its newly designed "Keeping Animals Healthy",website ... important,role of public policy in providing animal medicines ... are becoming more aware of the relationship between ...
... Filed in ... ... KV Pharmaceutical,Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical,company that ... pharmaceutical,products, announced today that it has reached a comprehensive settlement,agreement ...
... Clinical Trial Results on Preoperative Chemotherapy in Early Breast ... no better than six cycles in women with early ... according to data from a randomized controlled trial. Additionally, ... cycles of one drug combination did not benefit from ...
... of the main obstacles towards progress in the developing ... that have not been seriously addressed by the public ... new book, Forgotten People, Forgotten Diseases, published by ASM ... the world have too long been ignored. Parasitic ...
... Ultravist(R) are part of Amerinet,s Portfolio of ... Contracted ... HealthCare,Pharmaceuticals Inc., a leader in diagnostic imaging, announced today that,the ... to make,Magnevist(R) (gadopentetate dimeglumine) injection and Ultravist(R),(iopromide) injection available to ...
Cached Medicine News:Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 2Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 3Health News:Other highlights in the April 8 JNCI 2Health News:Other highlights in the April 8 JNCI 3Health News:Other highlights in the April 8 JNCI 4Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 2Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 3Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 4
... The new Primus PDQ Plus for the determination ... and accurate results. The PDQ Plus is a ... on-line barcode reading for the ultimate in safety ... affinity which is well known to be interference-free ...
Micromat II Hemoglobin A1c instrument is an easy-to-use, accurate and precise instrument with an requirement of only 10 L of capillary or venous sample....
... Cascade M-4 is a manual hemostasis ... routine clotting assays - PTs, aPTTs, ... for easy, inexpensive, low-volume testing, this ... big on features, offering time and ...
... a fully automated, benchtop coagulation workstation ... immunological assays in true random access ... sample management offers high throughput and ... the need to interrupt current testing. ...
Medicine Products: